Journal article · Hearing aids← The news desk

✦ The Dispatch

NAL-NL3: Advancing Hearing Aid Prescription for Modern Clinical Practice

A dispatch from Hearing Review — filed

Infographic showing the NAL-NL3 Fitting System with two components: NAL-NL3 Prescription for general clinical use and NAL-NL3 Modules including Comfort in Noise, Minimal Hearing Loss, and future modul
✦ PlateInfographic showing the NAL-NL3 Fitting System with two components: NAL-NL3 Prescription for general clinical use and NAL-NL3 Modules including Comfort in Noise, Minimal Hearing Loss, and future modul

This article provides clinical and research evidence to support the use of the new NAL-NL3 prescription for hearing aid fittings. By Vicky Zhang, Justin Zakis, Padraig Kitterick, and Brent Edwards Over the past several decades, the National Acoustic Laboratories (NAL) has been leading the development of widely adopted hearing aid prescriptions....

Continue reading at Hearing Review

✦ The floor

Discussion

Signed responses from readers of the wire.

✦ Clinical Takeaway ✦

Audiologists using NAL-NL2 should monitor adoption timelines and supporting evidence for NAL-NL3; the formula is not yet universally implemented in fitting software, so practice change depends on manufacturer integration and further peer-reviewed validation of clinical outcomes versus NAL-NL2.

✦ Why It Matters ✦

NAL-NL3 represents the first major update to the dominant NAL prescription family in over a decade, with machine-learning-derived targets and population-specific modules that could meaningfully shift hearing aid fitting standards worldwide.

✦ Key Points ✦
  1. 01NAL-NL3 is developed by Australia's National Acoustic Laboratories, succeeding NAL-NL2 after 10+ years.
  2. 02The formula incorporates machine learning and optimisation techniques to refine prescriptive gain targets.
  3. 03Specialised modules include a Comfort in Noise Module and a Minimal Hearing Loss Module.
  4. 04Additional modules are planned, suggesting an extensible, modular framework rather than a single static formula.
  5. 05Clinical and research evidence supporting NAL-NL3 is authored by Zhang, Zakis, Kitterick, and Edwards.
✦ Claims & Evidence ✦

NAL-NL3 incorporates 10+ years of real-world data from NAL-NL2 clinical use to improve prescriptive targets.

studypartially supported

NAL-NL3 leverages machine learning and optimisation advances to produce improved hearing aid gain targets.

studypartially supported

NAL-NL3 includes specialised modules for comfort in noise and minimal hearing loss populations.

press releasesupported

NAL-NL3 targets result in better patient outcomes compared to NAL-NL2.

studyunclear
✦ Research metadata ✦
Journal
Hearing Review
Publication type
research_article
Evidence level
2b
Population
Adults with hearing loss fitted with hearing aids; clinical and research evidence base used to develop and validate NAL-NL3 targets
Intervention
NAL-NL3 hearing aid prescription formula
Comparator
NAL-NL2 prescription formula

Primary outcomes

Prescriptive gain targets accuracy vs. preferred listening levels; Patient-reported outcomes in noise and minimal hearing loss populations; Clinical adoption feasibility of NAL-NL3 modules

✦ Related stories ✦